Welcome to the CREO Peroral Endoscopic Myotomy (POEM) Registry

Creo Medical Group plc (AIM: CREO), the medical device company, focused on the emerging field of surgical endoscopy, announces that early experience of the Company’s Speedboat™ Inject device has shown that it is feasible for performing peroral endoscopic myotomy (POEM) with a good safety profile. The abstract was authored by experts in the field of Gastrointestinal (‘GI’) therapeutics endoscopy, including Dr. Amit Maydeo an internationally renowned Gastroenterologist and endoscopy expert, known for his pioneering efforts on therapeutic endoscopy.

The main advantages of using Speedboat Inject were highlighted as reducing the risk of injury to the mucosa by the orientation of the hull and use of bipolar radiofrequency, which then aided quick tissue healing and resulted in quicker post-procedural recovery. Speedboat also reduced the overall procedure time, as no device changes were needed for bleeding vessels.

The video abstract, published via an open access content publisher, Thieme Group titled: ‘Feasibility of Speedboat RS2 with bipolar radiofrequency energy for peroral endoscopic myotomy in patients with achalasia (with video)’ can be viewed online here: https://www.thieme-connect.com/products/ejournals/html/10.1055/a-1165-0087

Dr Amit Maydeo & Craig Gulliford

Please click here for access to the LIVE registry.